Bliss GVS Pharma Limited

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has updated the contact details of its Key Managerial Personnel (KMPs) responsible for reporting material events to stock exchanges.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has submitted a disclosure under SEBI Takeover Regulations, indicating a potential takeover or acquisition activity.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding allotment of 187,750 securities pursuant to ESOP/ESPS at its meeting held on July 07, 2026, increasing the issued, subscribed & paid-up share capital of the Company.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about the resignation of a Director/KMP/SMP.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has appointed Mr. Rahul Adakmol as Chief Executive Officer with effect from July 15, 2026, and Mr. Santosh Parab as an Additional Director in the capacity of Non-Executive Non-Independent Director with effect from July 03, 2026. Mr. Narsimha Shibroor Kamath has stepped aside from the position of Chief Executive Officer with effect from close of business hours on July 14, 2026.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding Resignation of Mr Narsimha Shibroor Kamath as Chief Executive Officer of the company w.e.f. July 14, 2026. The Board of Directors has appointed Mr. Santosh Parab as an Additional Director and Mr. Rahul Adakmol as Chief Executive Officer.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has appointed Mr. Santosh Parab as a Non-Executive Director and Mr. Rahul Adakmol as the Chief Executive Officer, effective July 03, 2026 and July 15, 2026 respectively. Mr. Narsimha Shibroor Kamath has stepped aside as Chief Executive Officer and will continue as Managing Director.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 03, 2026. The Board of Directors has considered and approved the appointment of Mr. Santosh Parab as an Additional Director and Mr. Rahul Adakmol as Chief Executive Officer. Mr. Narsimha Shibroor Kamath has stepped aside from the position of Chief Executive Officer with effect from July 14, 2026.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has closed its trading window for insiders and designated persons from July 1, 2026, until 48 hours after the announcement of unaudited financial results for the quarter ended June 30, 2026.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about a copy of the newspaper publication regarding the publication of the newspaper advertisement of the notice of the 41st Annual General Meeting, e-Voting, and Book Closure Information.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has submitted a disclosure under SEBI Takeover Regulations, indicating a potential takeover or acquisition activity.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited announced a book closure period from July 9, 2026, to July 15, 2026, for its 41st Annual General Meeting. This period will also serve as the record date for determining eligible shareholders for the final dividend for the financial year ended March 31, 2026. If approved at the AGM on July 15, 2026, the final dividend will be paid on or before August 14, 2026.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has announced a record date of July 08, 2026, for the purpose of its Final Dividend for the financial year ended March 31, 2026. The Register of Members and Share Transfer Books will be closed from July 09, 2026, to July 15, 2026, for the 41st Annual General Meeting and dividend payment. If approved at the AGM, the dividend will be distributed to eligible shareholders on or before August 14, 2026.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited announced its 41st Annual General Meeting (AGM) will be held on July 15, 2026, via Video Conference. Key agenda items include the adoption of the audited financial statements for FY2025-2026, the proposed declaration of a final dividend of 100% (INR 1.00 per equity share), and the re-appointment of Mr. Narsimha Shibroor Kamath as Managing Director & CEO. The record date for the dividend is set for July 08, 2026, with payment expected by August 14, 2026, if approved.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the exchanges about a communication sent to its shareholders regarding the tax deduction on dividend income. Following the Finance Act, 2020, dividend distribution tax has been abolished, and dividend income is now taxable directly in the hands of shareholders. The company has emailed shareholders with registered IDs, explaining the new tax deduction process. This communication details the formalities shareholders must follow to ensure appropriate tax deduction on any dividend declared at the 41st Annual General Meeting for FY 2026-2027. Investors should review this information to understand their tax obligations for future dividend payouts.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about the intimation of its 41st Annual General Meeting (AGM) through newspaper publications dated June 19, 2026. The AGM is scheduled to take place on Wednesday, July 15, 2026, at 11:00 a.m. (IST). It will be conducted virtually via Video Conferencing (VC) or Other Audio Visual Means (OAVM). This routine announcement ensures shareholders are duly informed about the upcoming meeting where significant company matters are typically discussed and voted upon, in compliance with SEBI Listing Regulations.